Bio-Techne Stock

Bio-Techne Gross Profit

The Gross Profit of Bio-Techne (TECH) as of Aug 19, 2026 is 799.07 M USD. In the previous year, Gross Profit was 790.27 M USD — a change of 1.11% (higher).

Gross Profit

799.07 MUSD

YoY

1.11%

Last updated:

Gross Profit of Bio-Techne is 2026 799.07 M USD. Gross Profit of Bio-Techne was 2025 790.27 M USD. It decreases by 1.11% higher compared to the previous year.

The Bio-Techne Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2023
67.72 base
Jan 1, 2024
66.41 base
Jan 1, 2025
64.80 base
Jan 1, 2026
65.77 base
Jan 1, 2027 (e)
63.22 base
Jan 1, 2028 (e)
57.78 base
Jan 1, 2029 (e)
52.79 base
Jan 1, 2030 (e)
51.24 base
YEARGROSS MARGIN (%)
2030 est 51.24
2029 est 52.79
2028 est 57.78
2027 est 63.22
2026 65.77
2025 64.80
2024 66.41
2023 67.72
2022 68.42
2021 67.97
2020 65.41
2019 66.31
2018 67.21
2017 66.53
2016 67.46
2015 67.94
2014 70.27
2013 74.41
2012 74.96
2011 77.57
2010 79.76
2009 78.98
2008 79.45
2007 79.12
Access this data via the Eulerpool API

Bio-Techne Revenue

Bio-Techne Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.14 B USD
306.75 M USD
285.26 M USD
Jan 1, 2024
1.16 B USD
206.69 M USD
168.11 M USD
Jan 1, 2025
1.22 B USD
106.97 M USD
73.40 M USD
Jan 1, 2026
1.22 B USD
251.89 M USD
181.86 M USD
Jan 1, 2027 (e)
1.26 B USD
258.96 M USD
326.38 M USD
Jan 1, 2028 (e)
1.38 B USD
283.85 M USD
370.22 M USD
Jan 1, 2029 (e)
1.51 B USD
310.66 M USD
427.24 M USD
Jan 1, 2030 (e)
1.56 B USD
320.11 M USD
424.85 M USD

Bio-Techne Margins

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
67.72 %
26.99 %
25.10 %
Jan 1, 2024
66.41 %
17.83 %
14.50 %
Jan 1, 2025
64.80 %
8.77 %
6.02 %
Jan 1, 2026
65.77 %
20.73 %
14.97 %
Jan 1, 2027 (e)
65.77 %
20.49 %
25.82 %
Jan 1, 2028 (e)
65.77 %
20.53 %
26.77 %
Jan 1, 2029 (e)
65.77 %
20.53 %
28.23 %
Jan 1, 2030 (e)
65.77 %
20.53 %
27.24 %

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Gross Profit of Bio-Techne is 799.07 M USD in 2026.

Gross Profit of Bio-Techne changed from 790.27 M USD to 799.07 M USD, representing a 1.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Bio-Techne historically and in real time.

Access this data via the Eulerpool API

Income Statement — Bio-Techne

All Key Metrics — Bio-Techne